MEDIFAST (MED)
(Delayed Data from NYSE)
$35.51 USD
+1.80 (5.34%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $29.03 -6.48 (-18.25%) 7:58 PM ET
5-Strong Sell of 5 5
A Value B Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MED 35.51 +1.80(5.34%)
Will MED be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MED based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MED
Medifast's (MED) Transformation on Track Amid Macro Headwinds
MEDIFAST (MED) Down 11.5% Since Last Earnings Report: Can It Rebound?
MED: What are Zacks experts saying now?
Zacks Private Portfolio Services
Medifast (MED) Soars 5.9%: Is Further Upside Left in the Stock?
Innovations Aid Medifast (MED), Lower Customer Attraction Ails
Medifast (MED) Q4 Earnings Beat Estimates, Revenues Dip Y/Y
Other News for MED
Medifast: Q1 Earnings Snapshot
Medifast Announces First Quarter 2024 Financial Results
Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
MED Stock Earnings: Medifast Misses EPS, Beats Revenue for Q1 2024
Fly Intel: After-Hours Movers